GSK is finally settling Zantac litigation with manageable terms, removing a major overhang. Arexvy RSV vaccine is being squeezed by Pfizer and Moderna competition in the same season. HIV franchise (Tivicay, Dovato) faces increasing GLP-1 prescriber competition for primary care attention. Shingrix remains a steady performer. Pipeline lacks a clear blockbuster catalyst.
Thesis reviewed May 29, 2026
GSK plc is headquartered in United Kingdom, which is currently showing moderate signals.
π¬π§United Kingdom66NEUTRALView United Kingdom risk detail βπPharma0NEUTRAL| Ticker | Company | Score | Gap | Signal Ξ | Action |
|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 50 | +8% | β0% | NEUTRAL |
| LLY | Eli Lilly and Company | 50 | +24% | β0% | EARLY |
| REGN | Regeneron Pharmaceuticals Inc. | 50 | -16% | β0% | AVOID |
| RDY | Dr Reddy's Laboratories Ltd | 50 | +7% | β0% | NEUTRAL |
| TAK | Takeda Pharmaceutical Company Limited | 50 | +10% | β0% | NEUTRAL |
| SNY | Sanofi | 50 | +14% | β0% | EARLY |
| NVO | Novo Nordisk A/S | 50 | +15% | β0% | EARLY |
Investors who hold GSK may also have indirect exposure through these country funds.
GSK reaches $2.2B Zantac global settlement framework
Arexvy season-2 uptake softer than Pfizer Abrysvo
HIV pipeline candidate misses on Phase 2 durability
Estimates Β· Yahoo Finance Β· Not audited figures
| Politician | Party | Type | Amount | Trade Date | Return |
|---|---|---|---|---|---|
| Marjorie Taylor Mrs GreeneGA | R | Buy | $1kβ$15k | Nov 25, 24 | +56.2% |
| Marjorie Taylor Mrs GreeneGA | R | Buy | $1kβ$15k | Sep 3, 24 | +22.5% |